Skip to content
DataLookout
Menu

VAY RE-HITNCT07039422

Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab

StatusWithdrawn
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 14 versions: 14 with changes below. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial status changed: Recruiting → Withdrawn Sponsor's reason: The study was discontinued due to evolving scientific \& feasibility considerations that could adversely affect recruitment, thereby reducing the likelihood of generating a sufficiently robust dataset to support reliable efficacy \& safety conclusions. Show 4 more changesShow less
    • Enrollment target: estimated 60 to confirmed 0
    • Trial sites reduced: 25 → 0 locations
    • Eligibility criteria expanded, about 14 words
    • Secondary endpoints: details revised at 6 of 10 entries
  2. Minor Trial sites expanded: 22 → 25 locationsv13
  3. Minor Trial sites expanded: 18 → 22 locationsv12
  4. Notable Start date: Apr 27, 2026 to Jun 26, 2026
    • Trial sites expanded: 14 → 18 locations
    v11
  5. Minor Trial sites expanded: 10 → 14 locationsv10
Show 8 earlier versionsHide 8 earlier versions
  1. Minor Study sites: 9 to 10v9
  2. Minor Study sites: 4 to 9v8
  3. Notable Start date: Jan 30, 2026 to Apr 27, 2026
    • Study sites: 1 to 4
    v7
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v6
  5. Notable Start date: Oct 3, 2025 to Jan 30, 2026v5
  6. Notable Start date: Aug 1, 2025 to Oct 3, 2025v4
  7. Minor Secondary endpoints: 9 to 10v3
  8. Minor Study title shortened, about 1 wordv2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Treatment failure free (yes, no) for participants with Immune Thrombocytopenia (ITP)
Timeframe: From treatment start date until the events indicative of treatment failure (up to 2 years after last dose)
Durable response for participants with Warm Autoimmune Hemolytic Anemia (wAIHA)
Timeframe: At least 8 consecutive weeks, between week 9 and week 25

Secondary (10)

Response rate in participants with ITP only
Complete response rate in participants with ITP only
Number and percentage of participants receiving new ITP therapy only
Response and complete response in participants with wAIHA only
Number and percentage of participants receiving new wAIHA therapy only
Show 5 moreShow less
Number and percentage of participants receiving rescue treatment
Number of severe infections and percentage of participants with severe infection
Ianalumab concentration in serum
Incidence of anti-ianalumab antibodies in serum (ADA assay) over time
Titer of anti-ianalumab antibodies in serum (ADA assay) over time

Arms and interventions

Treatment arm 1Experimental

Participants will receive ianalumab lower dose

Treatment arm 2Experimental

Participants will receive ianalumab higher dose

Biologicals: Ianalumab